{"id":"https://genegraph.clinicalgenome.org/r/eadc4baf-54b0-4d3b-983e-34af2d397197v1.0","type":"EvidenceStrengthAssertion","dc:description":"Beta-thalassemias have long been recognized as inherited abnormalities of hemoglobin structure that result in anemias from early childhood when fetal hemoglobin expression is diminished.  These recessive disorders occur with high frequency among populations that have historically inhabited parts of the world where malaria is endemic. The inherited basis was first traced to partial or complete deletions in the *HBB* locus encoding the hemoglobin beta chain in 1975 (Ottolenghi et al., PMID: 49057), followed by the identification of specific HBB variants in two subsequent studies (PMID: 88735, PMID: 287080). Please note that earlier publications had previously identified the molecular basis of beta-thalassemia at the protein level through sequencing of the HBB gene product (PMID: 5863839, PMID: 6025643, PMID: 6038175). Individuals with biallelic *HBB* disruption are generally diagnosed with beta-thalassemia major or beta-thalassemia intermedia, depending on severity. Genotype is strongly correlated with phenotype, with higher severity associated with absence of detectable beta chains (beta-zero-thalassemia), and milder cases associated with the persistence of some detectable beta globin (beta-plus-thalassemia). Less severe forms of disease can also have milder anemia, due to moderately increased HbA2 hemoglobin and persistence of hemoglobin F, and reduced or no dependency on transfusions. The clinical and laboratory features of severely affected individuals include erythrocyte abnormalities such as hypochromic microcytic anemia, anisopoikilocytosis, elliptocytosis, decreased mean corpuscular volume, basophilic stippling, and dependence on blood transfusions with many disease phenotypes secondary to extramedullary hematopoiesis, e.g. splenomegaly and chronic transfusions resulting in iron overload. Characteristic abnormalities in hemoglobin itself include lack of beta-hemoglobin production, reduced hemoglobin A, increased HbA2 hemoglobin, and persistence of hemoglobin F later into childhood. Heterozygous carriers of causal variants are referred to as having beta-thalassemia minor or beta-thalassemia trait and can be mildly or sub-clinically affected. Per criteria outlined by the ClinGen Lumping & Splitting Working Group, the molecular mechanism has been found to be consistent between cases harboring biallelic and monoallelic loss-of-function variants in *HBB*. However, the dramatic difference in phenotypic severity and penetrance between the biallelic and monoallelic cases distinguishes them as two different conditions rather than a single spectrum of disease. Therefore, cases of beta-thalassemia major or beta-thalassemia intermedia caused by biallelic *HBB* variants have been separately curated here for beta-thalassemia HBB/LCRB (MONDO:0013517). Cases of beta-thalassemia caused by dominant *HBB* variants in the heterozygous state have been found to cause disease through a different mechanism, and have been evaluated for dominant beta thalassemia (MONDO:0011381, MIM #603902) in a separate curation.\n\nTen suspected disease-causing variants have been scored as part of this curation (one missense, two nonsense, three frameshift, two disrupting splicing, one partial gene deletion, and one disrupting the first nucleotide of the 5â€™ UTR). These have been collectively reported in nine probands in four publications (PMID: 88735, PMID: 1581247, PMID: 287080, PMID: 3683554, PMID: 18196920, PMID: 12752111, PMID: 27263053). The mechanism of pathogenicity appears to be biallelic loss of *HBB* function conferred by null and/or hypomorphic variants. Six out of nine probands were homozygous for their respective variants, while three probands were compound heterozygous. It has been established that the phenotype can also result from variants that disrupt a critical enhancer upstream of the *HBB* coding region (PMID: 1689188, PMID: 93487), although some of these variants disrupt the *HBD* locus as well. Evidence that the phenotype co-segregates with the homozygous genotype in a large family also contributed to the scoring of the gene-disease relationship (PMID: 18196920). A large amount of additional case-level evidence is available in the literature but was not included in this curation as the maximum score for this category of evidence had already been reached.\n\nThis gene-disease association is also supported by experimental evidence that the expression pattern of *HBB* across human tissues is highly restricted to the blood (PMID: 23715323). Extensive biochemical studies indicate that *HBB* encodes the beta chain of hemoglobin, which binds and releases oxygen as part of its function central to the role of red blood cells in carrying oxygen to the tissues of the body (PMID: 11747442). HBB protein interacts with the alpha hemoglobin chain encoded by the *HBA1* and *HBA2* genes (PMID: 6644819), which can harbor variants associated with the closely related condition alpha-thalassemia. Mouse models of *Hbb* loss of function recapitulate features of human beta-thalassemia patients such as hypochromic microcytic anemia, reduced hemoglobin A, abnormal erythrocyte morphology, splenomegaly, reticulocytosis, Heinz bodies, anisopoikilocytosis, presence of target cells, bone marrow hypercellularity, and abnormal iron deposition (PMID: 7568113, PMID: 9490703). CRISPR/Cas9-based editing of the mouse mutation in one case resulted in significant rescue of anemia, low hemoglobin concentration, anisocytosis and poikilocytosis, bone marrow proliferation, iron accumulation, and splenomegaly (PMID: 34706494).\n\nIn summary, *HBB* is definitively associated with autosomal recessive inheritance of beta-thalassemia. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Definitive classification. This classification was approved by the ClinGen General Gene Curation Expert Panel on April 26th, 2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/eadc4baf-54b0-4d3b-983e-34af2d397197","GCISnapshot":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10026","date":"2023-05-14T20:30:56.047Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10026","date":"2023-04-26T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa0371bf-8301-40ff-84c6-92866421f92b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6fa04c1f-6f2c-40d6-b142-b0ca140d844d","type":"EvidenceLine","dc:description":"NM_000518.5(HBB):c.126_129del (p.Phe42LeufsTer19) is a deletion variant in exon 2 predicted to trigger a frameshift and nonsense-mediated decay or to at least truncate the C-terminal 69% of the protein product. Down-scoring has been performed to account for previous scoring of this variant in a separate proband from this curation.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6fa04c1f-6f2c-40d6-b142-b0ca140d844d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","allele":{"id":"https://genegraph.clinicalgenome.org/r/77a0f485-c65b-4f06-bb7c-49e1228f7ffc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.126_129del (p.Phe42LeufsTer19)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA125284"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/d3c9349e-3b99-437d-9f1d-3be53adfd558","type":"EvidenceLine","dc:description":"Down-scoring has been performed to account for previous scoring of this variant in a separate proband from this curation.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3c9349e-3b99-437d-9f1d-3be53adfd558_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000518.5(HBB):c.48G>A (p.Trp16Ter) is a nonsense variant in exon 1 of 3, and would be predicted to trigger nonsense-mediated decay. However, systematic analysis of HBB nonsense transcript abundance (PMID: 21389146) found that nonsense variants in this region only decreased variant mRNA abundance to 70-90% of normal expression. On the other hand, the variant is predicted to truncate the C-terminal 90% of the protein product. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d3c9349e-3b99-437d-9f1d-3be53adfd558_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","allele":{"id":"https://genegraph.clinicalgenome.org/r/675a7bef-f759-461a-9fd5-aa401710f1e5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.47G>A (p.Trp16Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA125261"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/fa0371bf-8301-40ff-84c6-92866421f92b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","rdfs:label":"Yasmeen_2016_Proband_3","allele":[{"id":"https://genegraph.clinicalgenome.org/r/675a7bef-f759-461a-9fd5-aa401710f1e5"},{"id":"https://genegraph.clinicalgenome.org/r/77a0f485-c65b-4f06-bb7c-49e1228f7ffc"}],"detectionMethod":"Genotyping appears to have included the HBA1, HBA2, HBG2, and HBB genes using multiplex GAP PCR and RFLP-based PCR, as well as Sanger sequencing.","firstTestingMethod":"PCR","phenotypeFreeText":"The patient belongs to a cohort that has a diagnosis of transfusion-dependent beta thalassemia, with the specific phenotype identified as beta-0 thalassemia.","phenotypes":["obo:HP_0004840","obo:HP_0025548","obo:HP_0025066"],"previousTestingDescription":"Previous testing appears to have included genotyping of the HBA1, HBA2, HBG2, and HBB genes.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d3c9349e-3b99-437d-9f1d-3be53adfd558_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6fa04c1f-6f2c-40d6-b142-b0ca140d844d_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d50ade1d-2fb9-4cce-aac7-6c0f2a730b70_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/436d4ce0-db48-4d59-be32-e19b42ed2047","type":"EvidenceLine","dc:description":"NM_000518.5(HBB):c.52A>T (p.Lys18Ter) is a nonsense variant in exon 1 of 3, and is predicted to trigger nonsense-mediated decay or to at least truncate the C-terminal 88% of the protein product. Despite the presence of functional evidence that this is a null variant, moderate down-scoring has been performed due to the homozygous state of the variant and the limitations of the genotyping method. Further down-scoring has not been performed for the evidence of evasion of nonsense-mediated decay since the variant fails to undergo translation.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/436d4ce0-db48-4d59-be32-e19b42ed2047_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Red blood cells from the patient showed no protein synthesis was occurring in vivo, despite the presence of the mRNA (PMID: 268654). Isolated mRNA from red blood cells supported gamma and alpha-hemoglobin synthesis but no HBB synthesis in a wheat germ cell-free in vitro system.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/436d4ce0-db48-4d59-be32-e19b42ed2047_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/88735","allele":{"id":"https://genegraph.clinicalgenome.org/r/66dc4405-3328-4e05-abd1-b58d42318b51","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.52A>T (p.Lys18Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA125257"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d50ade1d-2fb9-4cce-aac7-6c0f2a730b70","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/88735","rdfs:label":"Chang_1979_Proband_1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":28,"allele":{"id":"https://genegraph.clinicalgenome.org/r/66dc4405-3328-4e05-abd1-b58d42318b51"},"detectionMethod":"cDNA-RNA hybridization and RNA fingerprint analysis previously showed that the mRNA was present but not translated. This motivated partial Sanger sequencing of the HBB mRNA to detect the variant.","firstTestingMethod":"Other","phenotypeFreeText":"The patient has a diagnosis of beta-0 thalassemia, which indicates that beta-globin production is absent. The patient did not undergo transfusions for a 10 year period, after developing antibodies against multiple erythrocyte antigens (PMID: 268654)","phenotypes":["obo:HP_0011904","obo:HP_0001903","obo:HP_0011905","obo:HP_0031851","obo:HP_0045048"],"previousTesting":true,"previousTestingDescription":"Previous genotyping consisted of cDNA-RNA hybridization and RNA fingerprint analysis, showing that the mRNA was present but not translated (PMID: 268654).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/436d4ce0-db48-4d59-be32-e19b42ed2047_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/21d7d09d-40fb-4c85-ac98-c8c54faee3f5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e915e7d-c1f2-42c9-910f-7048e11f7fa2","type":"EvidenceLine","dc:description":"Moderate up-scoring of the variant was considered for its independent occurrences in unrelated probands with different haplotypes, but ultimately scoring was avoided due to the lack of detailed phenotypes available.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e915e7d-c1f2-42c9-910f-7048e11f7fa2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000518.5(HBB):c.79G>A (p.Glu27Lys) is a missense variant that is responsible for a large percentage of beta-thalassemia cases and is found in many published probands. This paper shows that it occurs in probands across multiple haplotypes, indicating independent occurrences (PMID: 12752111).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5e915e7d-c1f2-42c9-910f-7048e11f7fa2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12752111","allele":{"id":"https://genegraph.clinicalgenome.org/r/f4cacb9e-fc64-4cda-b0c3-c4a96b16c0d3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.79G>A (p.Glu27Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA124838"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/21d7d09d-40fb-4c85-ac98-c8c54faee3f5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12752111","rdfs:label":"Fisher_2003_proband_2","allele":{"id":"https://genegraph.clinicalgenome.org/r/f4cacb9e-fc64-4cda-b0c3-c4a96b16c0d3"},"detectionMethod":"Genotyping appears to have started with included ARMS-PCR for known HBB variants, with negative results, followed by Sanger sequencing of coding sequences and flanking regions of the HBB locus within PCR-amplified patient DNA samples. Haplotype analysis was subsequently performed, showing that all occurrences of the variant were on a single haplotype. Limited HBA1 and HBA2 genotyping was also performed by Southern blotting to test for copy number / deletion forms of alpha-thalassemia.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has a diagnosis of thalassemia major or intermedia.","previousTesting":true,"previousTestingDescription":"Previous testing appears to have included ARMS-PCR for known HBB variants, with negative results.","secondTestingMethod":"Other","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/5e915e7d-c1f2-42c9-910f-7048e11f7fa2_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6297fc15-1b1e-4b04-b514-95c4f10baffd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ddbbfccb-09f0-496a-ab47-3a73a32d436b","type":"EvidenceLine","dc:description":"The variant removes the final exon (PMID: 6251466) and is predicted to truncate the C-terminal 29% of the protein product. It has been observed in multiple apparently unrelated probands across ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ddbbfccb-09f0-496a-ab47-3a73a32d436b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","allele":{"id":"https://genegraph.clinicalgenome.org/r/19f0d082-2f76-4f2e-b92d-30860a6e38a9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000011.10:g.5225389_5226007del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA916083169"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6d1d53f9-40aa-4f27-a546-81b4b954844c","type":"EvidenceLine","dc:description":"NM_000518.5(HBB):c.92+1G>T is a splice variant that disrupts a canonical splice site. Down-scoring has been performed for lack of a demonstrated impact on the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d1d53f9-40aa-4f27-a546-81b4b954844c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","allele":{"id":"https://genegraph.clinicalgenome.org/r/b31f53ce-7535-4c62-9663-d6871ec7bd03","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.92+1G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA125304"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6297fc15-1b1e-4b04-b514-95c4f10baffd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","rdfs:label":"Yasmeen_2016_Proband_1","allele":[{"id":"https://genegraph.clinicalgenome.org/r/b31f53ce-7535-4c62-9663-d6871ec7bd03"},{"id":"https://genegraph.clinicalgenome.org/r/19f0d082-2f76-4f2e-b92d-30860a6e38a9"}],"detectionMethod":"Genotyping appears to have included genotyping of the HBA1, HBA2, HBG2, and HBB genes using multiplex GAP PCR and RFLP-based PCR, as well as Sanger sequencing.","firstTestingMethod":"PCR","phenotypeFreeText":"The patient belongs to a cohort that has a diagnosis of transfusion-dependent beta thalassemia, with the specific phenotype identified as beta-0 thalassemia.","phenotypes":["obo:HP_0025066","obo:HP_0025548","obo:HP_0004840"],"previousTesting":true,"previousTestingDescription":"Previous testing appears to have included genotyping of the HBA1, HBA2, HBG2, and HBB genes.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/6d1d53f9-40aa-4f27-a546-81b4b954844c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ddbbfccb-09f0-496a-ab47-3a73a32d436b_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/25d436da-898f-4038-89b5-fc738f1473c3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb0aeffe-fb21-42ae-9680-dae05d923a51","type":"EvidenceLine","dc:description":"The variant has been down-scored based on the homozygous state and the limitations of the genotyping method. Further down-scoring has not been performed for the evidence of evasion of nonsense-mediated decay since other nearby nonsense variants have similarly been found to persist at the mRNA level yet fail to undergo translation (PMID: 88735).","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb0aeffe-fb21-42ae-9680-dae05d923a51_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000518.5(HBB):c.48G>A (p.Trp16Ter) is a nonsense variant in exon 1 of 3, and would be predicted to trigger nonsense-mediated decay. However, systematic analysis of HBB nonsense transcript abundance (PMID: 21389146) found that nonsense variants in this region only decreased variant mRNA abundance to 70-90% of normal expression. On the other hand, the variant is predicted to truncate the C-terminal 90% of the protein product.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/cb0aeffe-fb21-42ae-9680-dae05d923a51_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1581247","allele":{"id":"https://genegraph.clinicalgenome.org/r/867c0d2a-fbb9-4b07-a0fc-7288b080a2f3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.48G>A (p.Trp16Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA217115390"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/25d436da-898f-4038-89b5-fc738f1473c3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1581247","rdfs:label":"Ribeiro_1992_Subject_#2","allele":{"id":"https://genegraph.clinicalgenome.org/r/867c0d2a-fbb9-4b07-a0fc-7288b080a2f3"},"detectionMethod":"Genotyping appears to have been limited to Sanger sequencing of coding sequences and flanking regions of the HBB locus within patient DNA samples.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has a diagnosis of severe, transfusion-dependent anemia, implied to be equivalent to beta-thalassemia.","phenotypes":"obo:HP_0001903","previousTesting":false,"previousTestingDescription":"Previous testing appears to have been blood count-based rather than genotyping.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/cb0aeffe-fb21-42ae-9680-dae05d923a51_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6ab7504d-dcca-4818-b510-8435e649fda4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35ad8b9a-3502-4503-872b-df8178c21ba6","type":"EvidenceLine","dc:description":"NM_000518.5(HBB):c.166del (p.Met56fs) is a frameshift variant in exon 2 of 3, and is predicted to trigger nonsense-mediated decay or to at least truncate the C-terminal 63% of the protein product. Down-scoring was considered to account for the homozygous state of the variant and the limitations of the genotyping method. Ultimately scoring was avoided due to the lack of detailed phenotypes available.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35ad8b9a-3502-4503-872b-df8178c21ba6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12752111","allele":{"id":"https://genegraph.clinicalgenome.org/r/83c7ff79-3029-4ad2-9237-95df9754d9ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.166del (p.Met56TrpfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA916083200"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6ab7504d-dcca-4818-b510-8435e649fda4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12752111","rdfs:label":"Fisher_2003_proband_1","allele":{"id":"https://genegraph.clinicalgenome.org/r/83c7ff79-3029-4ad2-9237-95df9754d9ee"},"detectionMethod":"Genotyping appears to have started with included ARMS-PCR for known HBB variants, with negative results, followed by Sanger sequencing of coding sequences and flanking regions of the HBB locus within PCR-amplified patient DNA samples. Haplotype analysis was subsequently performed, showing that all occurrences of the variant were on a single haplotype. Limited HBA1 and HBA2 genotyping was also performed by Southern blotting to test for copy number / deletion forms of alpha-thalassemia.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient has a diagnosis of thalassemia major or intermedia.","previousTesting":true,"previousTestingDescription":"Previous testing appears to have included ARMS-PCR for known HBB variants, with negative results.","secondTestingMethod":"Other","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/35ad8b9a-3502-4503-872b-df8178c21ba6_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/337b7b51-05c0-4ef3-832f-c78c1c587762_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ef798cc-8f32-495f-8297-93e8b27f4fec","type":"EvidenceLine","dc:description":"NM_000518.5:c.-50A>C is a variant in the initial base pair (cap) of the HBB transcript, and does not have evidence of impact on expression or other characteristics at the protein level. The variant has been observed in the compound heterozygous state with multiple different variants and appears to be associated with some residual function (PMID: 27263053).","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ef798cc-8f32-495f-8297-93e8b27f4fec_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/3683554","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5cfb30a-8f56-43ef-9b34-9806274634d3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.-50A>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342845"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/337b7b51-05c0-4ef3-832f-c78c1c587762","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/3683554","rdfs:label":"Wong_1987_Proband_3","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5cfb30a-8f56-43ef-9b34-9806274634d3"},"detectionMethod":"Genotyping appears to have included haplotype analysis as well as Sanger sequencing of coding sequences and flanking regions of the HBB locus within PCR-amplified patient DNA samples.","firstTestingMethod":"Other","phenotypeFreeText":"The patient has a diagnosis of beta-thalassemia.","phenotypes":["obo:HP_0045048","obo:HP_0011904","obo:HP_0025066"],"previousTesting":true,"previousTestingDescription":"Previous testing appears to have included haplotype analysis.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2ef798cc-8f32-495f-8297-93e8b27f4fec_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/42f11df3-d7aa-4b95-ae4b-d15591bbdd6d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4be003c-9423-4d9f-90d1-31d9210205d4","type":"EvidenceLine","dc:description":"NM_000518.5(HBB):c.126_129del (p.Phe42LeufsTer19) is a deletion variant in exon 2 predicted to trigger a frameshift and nonsense-mediated decay or to at least truncate the C-terminal 69% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4be003c-9423-4d9f-90d1-31d9210205d4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","allele":{"id":"https://genegraph.clinicalgenome.org/r/77a0f485-c65b-4f06-bb7c-49e1228f7ffc"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0eec4f39-ebd9-4694-935c-e2f8c9613adb","type":"EvidenceLine","dc:description":"Default scoring is considered appropriate given the hypomorphic level of the variant and evidence of a partial splicing defect.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0eec4f39-ebd9-4694-935c-e2f8c9613adb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 6188062 reports a moderate defect in splicing.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0eec4f39-ebd9-4694-935c-e2f8c9613adb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","allele":{"id":"https://genegraph.clinicalgenome.org/r/8065a646-d423-4ed4-8056-e733cb98639d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.92+5G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA125310"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/42f11df3-d7aa-4b95-ae4b-d15591bbdd6d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27263053","rdfs:label":"Yasmeen_2016_Proband_2","allele":[{"id":"https://genegraph.clinicalgenome.org/r/77a0f485-c65b-4f06-bb7c-49e1228f7ffc"},{"id":"https://genegraph.clinicalgenome.org/r/8065a646-d423-4ed4-8056-e733cb98639d"}],"detectionMethod":"The method appears to have included genotyping of the HBA1, HBA2, HBG2, and HBB genes using multiplex GAP PCR and RFLP-based PCR, as well as Sanger sequencing.","firstTestingMethod":"PCR","phenotypeFreeText":"The patient belongs to a cohort that has a diagnosis of transfusion-dependent beta thalassemia, with the specific phenotype identified as beta-0 thalassemia.","phenotypes":["obo:HP_0004840","obo:HP_0025066","obo:HP_0025548"],"previousTesting":true,"previousTestingDescription":"Previous testing appears to have included genotyping of the HBA1, HBA2, HBG2, and HBB genes.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/0eec4f39-ebd9-4694-935c-e2f8c9613adb_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b4be003c-9423-4d9f-90d1-31d9210205d4_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/70e64fb3-fe76-47ef-bed9-ccb6463b2582_proband_segregation","type":"FamilyCosegregation","dc:description":"The pedigree should be included in the final eLOD calculation since the family meets the requirements for minimal affected members and complete segregation of the homozygous genotype with the affected phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18196920","rdfs:label":"Baig_2008_Family","estimatedLodScore":7.07,"family":{"id":"https://genegraph.clinicalgenome.org/r/70e64fb3-fe76-47ef-bed9-ccb6463b2582","type":"Family","rdfs:label":"Baig_2008_Family","member":{"id":"https://genegraph.clinicalgenome.org/r/ec209402-37b8-4bba-9570-f1b25627803f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18196920","rdfs:label":"Baig_2008_Family_proband_V-16","allele":{"id":"https://genegraph.clinicalgenome.org/r/02d487d3-4fcc-4f5a-8215-d2fe5ed97f8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000518.5(HBB):c.27dup (p.Ser10ValfsTer14)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA125282"}},"detectionMethod":"The proband has previously been genotyped, likely by Sanger sequencing. His affected and unaffected family members were then genotyped by amplification refractory mutation system (ARMS) PCR.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The proband has received a diagnosis of beta-thalassemia major. Red cell indices are reportedly abnormal, but have not been described in detail.","phenotypes":"obo:HP_0045048","previousTesting":true,"previousTestingDescription":"The proband has previously been genotyped, likely by Sanger sequencing. Other previous testing appears to have been phenotype- rather than genotype-based.","secondTestingMethod":"PCR","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/75678a6f-1c90-40a3-aa3c-52d220fc6a39_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18196920","allele":{"id":"https://genegraph.clinicalgenome.org/r/02d487d3-4fcc-4f5a-8215-d2fe5ed97f8e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Affected family members have received a diagnosis of beta-thalassemia. Red cell indices are reportedly abnormal, but have not been described in detail.","phenotypeNegativeAlleleNegative":18,"phenotypePositiveAllelePositive":9,"phenotypes":"obo:HP_0045048","proband":{"id":"https://genegraph.clinicalgenome.org/r/ec209402-37b8-4bba-9570-f1b25627803f"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ec209402-37b8-4bba-9570-f1b25627803f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75678a6f-1c90-40a3-aa3c-52d220fc6a39","type":"EvidenceLine","dc:description":"Down-scoring has been performed due to the known consanguinity of the parents (known to be members of the same extended family) and the limitations of the genotyping method.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75678a6f-1c90-40a3-aa3c-52d220fc6a39_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ec209402-37b8-4bba-9570-f1b25627803f"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9375c025-c156-492d-9e93-29628bb9eef1","type":"EvidenceLine","dc:description":"Default scoring has been performed to acknowledge the degree of match between the model phenotype and the features of the human patients. Up-scoring has been avoided due to the difference in mode of inheritance, with severity of the heterozygous animals comparable to homozygous humans, as well as the lack of clarity regarding the effect of the knocked in human variant. Control mice do not harbor a wild-type human transgene, so the phenotype likely results from the disruption of the endogenous locus rather than presence of the transgene.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/64484f62-a9e1-400d-900a-b2ca94afe474","type":"Finding","dc:description":"The model exhibits phenotypes consistent with beta-thalassemia intermedia, including anemia (Figure 4, Table 1), Anisocytosis, Poikilocytosis, iron deposition in the kidneys (text only), Extramedullary hematopoiesis (text only), and Splenomegaly. The model does have some differences from the human patients, such as the failure of homozygous animals to survive postnatally (matching another mouse model described in PMID: 7568113) and the strength of the phenotype in heterozygous animals despite the continued presence of a wild-type allele. These features indicate increased severity in the mouse model.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9490703","rdfs:label":"Mouse model with human HBB variant transgene knock-in","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/758bce95-32f5-4820-a836-9235938ce6aa","type":"EvidenceLine","dc:description":"The model has been scored for the specificity of the match to the human phenotype at the reticulocyte level. Down-scoring was considered to reflect the difference in the mode of inheritance between mice and humans, but was avoided due to other factors potentially underlying the greater severity in mice. These include the lack of availability of transfusions, or differences in the timing of the requirement for adult forms of hemoglobin.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa348369-b046-4b7c-b89f-82f603bb0e98","type":"Finding","dc:description":"The model is similar to but more severe than the human patient phenotype associated with heterozygous disruption of HBB. Abnormal red cell morphology is shown in Figure 4. Splenomegaly and inclusion bodies are shown in Figure 5. The mouse has other differences from the human patients, such as the need to delete two mouse Hbb orthologs whereas the human genome contains a single HBB gene. These features may underlie increased severity in the mouse model.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7568113","rdfs:label":"Mouse model harboring Hbb locus deletion","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/385452ac-d333-4433-925c-afff6a113991","type":"EvidenceLine","dc:description":"The experiment has been scored at default levels due to the use of a targeted gene editing method to reverse the variant, with broadly successful results.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bbe155fc-966a-4e3f-b214-05bf0da7dec8","type":"Finding","dc:description":"The rescue experiment resulted in significant reversal of prenatal death (Table 2), anemia (Table 1), low hemoglobin concentration (Table 1), anisocytosis and poikilocytosis (Figure 3), bone marrow proliferation (Figure 3), iron accumulation in the liver (Figure 3), and splenomegaly (Figure 4).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34706494","rdfs:label":"CRISPR-based rescue of mice harboring an HBB variant","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/10e10aac-d9cc-4422-8fb9-b206e642bb27_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e61526b-6373-4a76-a863-de987b2e146b","type":"EvidenceLine","dc:description":"Up-scoring has been performed due to the extent to which this biochemical function is well-established in the HBB literature.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/237cfaa7-8bbd-417f-8302-e9f97c282ac2","type":"Finding","dc:description":"The article provides an example of the function of HBB as a component of an oxygen-carrying complex (hemoglobin) that is central to the ability of red blood cells to oxygenate the body.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11747442","rdfs:label":"HBB encodes a hemoglobin chain that carries oxygen.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f657d7fb-681a-4bc9-accc-3467edc16569","type":"EvidenceLine","dc:description":"The interaction of HBB with alpha-hemoglobin links it physically with the protein product of the HBA1 and HBA2 genes. Up-scoring has been proposed since it provides a link to two different genes associated with alpha-thalassemia.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78830ea5-9339-44ea-9f4b-be512ce7daf7","type":"Finding","dc:description":"The human HBB protein has been co-crystallized with the product of the HBA1 gene (identical to that of the HBA2 gene) in the form of a multimeric complex (oxyhemoglobin). Variants in HBA1 and HBA2 have been associated with alpha-thalassemia, which shares many features with beta-thalassemia.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/6644819","rdfs:label":"HBB physically interacts with the HBA1/HBA2 gene product.","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/196c159f-84f5-4c92-8367-6c1fa05df01f","type":"EvidenceLine","dc:description":"Up-scoring has been recommended due to the high specificity of HBB expression within whole blood, which is consistent with the many hematological phenotypes of beta thalassemia (including severe anemia, iron overload, hypercoagulation resulting in thrombotic complications, and splenomegaly).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0877fac6-4d63-4088-b774-2252b97b98b3","type":"Finding","dc:description":"RNA-seq profiling of HBB expression across more than 50 human tissues identified highly specific expression in whole blood (https://gtexportal.org/home/gene/HBB).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23715323","rdfs:label":"HBB is specifically expressed in whole blood.","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":6227,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/-cJb15ELnVE","type":"GeneValidityProposition","disease":"obo:MONDO_0013517","gene":"hgnc:4827","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_10e10aac-d9cc-4422-8fb9-b206e642bb27-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}